ABCL – AbCellera Biologics Inc.
Name : AbCellera Biologics Inc.
Sector : Healthcare
Industry: Biotechnology
Mark. Cap: $0.0000
EPSttm :
[iframe https://s.tradingview.com/embed-widget/symbol-info/?locale=in&symbol=ABCL
#%7B%22symbol%22%3A%22A%22%2C%22width%22%3A%22100%25%22%2C%22colorTheme%22%3A%22light%22%2C%22isTransparent%22%3Atrue%2C%22height%22%3A203%2C%22utm_source%22%3A%22themarketstracker.com%22%2C%22utm_medium%22%3A%22widget_new%22%2C%22utm_campaign%22%3A%22symbol-info%22%7D 900 250 ]
[iframe https://api.stockdio.com/visualization/financial/charts/v1/PricesChange?app-key=F086EEE750E14D8D8A456DB88B2D6D8C&symbol=ABCL
&conditionalVolume=false&allowPeriodChange=false&tooltipsStyle=None&palette=Financial-Light&showBorderAndTitle=false 300 200 ]
Float Short %
10.27
Margin Of Safety %
Put/Call OI Ratio
0.22
EPS Next Q Diff
-0.02
EPS Last/This Y
-0.11
EPS This/Next Y
0.07
Price
2.1
Target Price
10
Analyst Recom
1.25
Performance Q
-28.81
Relative Volume
3.95
Beta
0.39
Ticker: ABCL
of 1
| Date | Symbol | Last | P/C OI | P/C Vol | Total OI |
|---|---|---|---|---|---|
| 2025-04-14 | ABCL | 2.45 | 0.20 | 0.03 | 26811 |
| 2025-04-15 | ABCL | 2.43 | 0.19 | 0.48 | 27079 |
| 2025-04-16 | ABCL | 2.4 | 0.20 | 0.77 | 27122 |
| 2025-04-17 | ABCL | 2.42 | 0.20 | 0.60 | 27131 |
| 2025-04-18 | ABCL | 2.42 | 0.20 | 0.49 | 27131 |
| 2025-04-21 | ABCL | 2.45 | 0.25 | 0.77 | 14945 |
| 2025-04-22 | ABCL | 2.52 | 0.26 | 0.00 | 15015 |
| 2025-04-23 | ABCL | 2.53 | 0.26 | 0.01 | 15049 |
| 2025-04-24 | ABCL | 2.6 | 0.25 | 1.33 | 15374 |
| 2025-04-25 | ABCL | 2.57 | 0.25688520594687 | 0.37575757575758 | 15471 |
| 2025-04-28 | ABCL | 2.59 | 0.26173955139584 | 0.014285714285714 | 15638 |
| 2025-04-29 | ABCL | 2.56 | 0.26 | 0.22 | 15655 |
| 2025-04-30 | ABCL | 2.62 | 0.26 | 0.09 | 15637 |
| 2025-05-01 | ABCL | 2.48 | 0.26 | 0.08 | 15928 |
| 2025-05-02 | ABCL | 2.4 | 0.26 | 0.16 | 15959 |
| 2025-05-05 | ABCL | 2.18 | 0.26 | 0.90 | 16353 |
| 2025-05-06 | ABCL | 2.02 | 0.26 | 0.28 | 16491 |
| 2025-05-07 | ABCL | 2.02 | 0.26 | 0.02 | 16824 |
| 2025-05-08 | ABCL | 2.01 | 0.25 | 0.06 | 17393 |
| 2025-05-09 | ABCL | 2.03 | 0.24 | 0.11 | 17791 |
| 2025-05-12 | ABCL | 2.06 | 0.23 | 0.03 | 18420 |
| 2025-05-13 | ABCL | 2.11 | 0.22 | 0.67 | 18093 |
| Date | Symbol | Last | P/C OI | P/C Vol | Total OI |
Current Page1 of 1
of 1
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
|---|---|---|---|---|---|
| 2025-04-14 | ABCL | 2.44 | -1.8 | - | -0.66 |
| 2025-04-15 | ABCL | 2.43 | -1.8 | - | -0.66 |
| 2025-04-16 | ABCL | 2.40 | -1.8 | - | -0.66 |
| 2025-04-17 | ABCL | 2.42 | -1.8 | - | -0.66 |
| 2025-04-18 | ABCL | 2.42 | -1.8 | - | -0.66 |
| 2025-04-21 | ABCL | 2.46 | -1.8 | - | -0.66 |
| 2025-04-22 | ABCL | 2.52 | -1.8 | - | -0.66 |
| 2025-04-23 | ABCL | 2.53 | -1.8 | - | -0.66 |
| 2025-04-24 | ABCL | 2.60 | -1.8 | - | -0.66 |
| 2025-04-25 | ABCL | 2.57 | -1.8 | - | -0.66 |
| 2025-04-28 | ABCL | 2.59 | -1.8 | - | -0.66 |
| 2025-04-29 | ABCL | 2.55 | -1.8 | - | -0.66 |
| 2025-04-30 | ABCL | 2.61 | -1.8 | - | -0.66 |
| 2025-05-01 | ABCL | 2.48 | -1.8 | - | -0.66 |
| 2025-05-02 | ABCL | 2.41 | -1.8 | - | -0.66 |
| 2025-05-05 | ABCL | 2.18 | -1.8 | - | -0.66 |
| 2025-05-06 | ABCL | 2.02 | -1.8 | - | -0.66 |
| 2025-05-07 | ABCL | 2.01 | -1.8 | - | -0.66 |
| 2025-05-08 | ABCL | 2.01 | -1.8 | - | -0.66 |
| 2025-05-09 | ABCL | 2.03 | -1.8 | - | -0.66 |
| 2025-05-12 | ABCL | 2.06 | -1.8 | - | -0.66 |
| 2025-05-13 | ABCL | 2.10 | -1.8 | - | -0.66 |
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
Current Page1 of 1
of 1
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
|---|---|---|---|---|
| 2025-04-14 | ABCL | 0.00 | 11.77 | 10.57 |
| 2025-04-15 | ABCL | 0.00 | 11.77 | 10.57 |
| 2025-04-16 | ABCL | 0.00 | 11.77 | 10.57 |
| 2025-04-17 | ABCL | 0.00 | 11.77 | 10.57 |
| 2025-04-18 | ABCL | 0.00 | 11.77 | 10.57 |
| 2025-04-21 | ABCL | 0.00 | 11.69 | 10.57 |
| 2025-04-22 | ABCL | 0.00 | 11.69 | 10.57 |
| 2025-04-23 | ABCL | 0.00 | 11.69 | 10.57 |
| 2025-04-24 | ABCL | 0.00 | 11.69 | 10.57 |
| 2025-04-25 | ABCL | 0.00 | 11.69 | 10.57 |
| 2025-04-28 | ABCL | 0.00 | 11.91 | 10.64 |
| 2025-04-29 | ABCL | 0.00 | 11.91 | 10.64 |
| 2025-04-30 | ABCL | 0.00 | 11.91 | 10.64 |
| 2025-05-01 | ABCL | 0.00 | 11.91 | 10.64 |
| 2025-05-02 | ABCL | 0.00 | 11.91 | 10.64 |
| 2025-05-05 | ABCL | 0.00 | 11.68 | 10.64 |
| 2025-05-06 | ABCL | 0.00 | 11.68 | 10.64 |
| 2025-05-07 | ABCL | 0.00 | 11.68 | 10.64 |
| 2025-05-08 | ABCL | 0.00 | 11.68 | 10.64 |
| 2025-05-09 | ABCL | 0.00 | 11.68 | 10.62 |
| 2025-05-12 | ABCL | 0.00 | 10.99 | 10.27 |
| 2025-05-13 | ABCL | 0.00 | 10.99 | 10.27 |
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
Current Page1 of 1
[iframe https://widget.finnhub.io/widgets/historical-eps?symbol=ABCL
589 360 ]
Last Quarter Act. EPS
-0.15
Avg. EPS Est. Current Quarter
-0.17
Avg. EPS Est. Next Quarter
-0.17
Insider Transactions
Institutional Transactions
10.99
Beta
0.39
Average Sales Estimate Current Quarter
7
Average Sales Estimate Next Quarter
6
Fair Value
Quality Score
25
Growth Score
34
Sentiment Score
16
Actual DrawDown %
97.1
Max Drawdown 5-Year %
Target Price
10
P/E
Forward P/E
PEG
P/S
27.11
P/B
0.61
P/Free Cash Flow
EPS
-0.57
Average EPS Est. Cur. Y
-0.66
EPS Next Y. (Est.)
-0.59
Target Price Estimates Raised
Target Price Estimates Lowered
1
Profit Margin
-726.23
Relative Volume
3.95
Return on Equity vs Sector %
-40.1
Return on Equity vs Industry %
-23.1
EPS 1 7Days Diff
EPS 1 30Days Diff
EBIT Estimation
[iframe https://widget.finnhub.io/widgets/recommendation?symbol=ABCL
589 450 ]
[iframe https://widget.finnhub.io/widgets/eps-estimate?symbol=ABCL
589 450 ]
AbCellera Biologics Inc.Sector: Healthcare
Industry: Biotechnology
Employees: 596
AbCellera Biologics Inc. engages in discovering and developing antibody-based medicines for indications with unmet medical need in the United States. Its product pipeline includes ABCL635, an antibody-drug candidate, which is in preclinical trial to treat metabolic and endocrine conditions; and ABCL575, a fully human, half-life extended monoclonal antibody, which is in preclinical trial for treating T-cell-mediated autoimmune conditions, such as atopic dermatitis. The company has a research collaboration and license agreement with Eli Lilly and Company; and partnership agreement with Viking Global Investors & ArrowMark Partners and Biogen Inc. AbCellera Biologics Inc. was incorporated in 2012 and is headquartered in Vancouver, Canada.
stock quote shares ABCL – AbCellera Biologics Inc. Stock Price stock today
news today ABCL – AbCellera Biologics Inc. stock forecast ,stock prediction 2023 2024 2025
marketwatch ABCL – AbCellera Biologics Inc. yahoo finance google finance
stock history ABCL – AbCellera Biologics Inc. invest stock market
stock prices ABCL
premarket after hours
ticker ABCL
fair value insiders trading